Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure.

Scarlett JM, Bowe DD, Zhu X, Batra AK, Grant WF, Marks DL.

J Endocrinol. 2010 Jul;206(1):121-30. doi: 10.1677/JOE-09-0397. Epub 2010 Apr 6.

2.

Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease.

Cheung WW, Mak RH.

Am J Physiol Renal Physiol. 2012 Nov 1;303(9):F1315-24. doi: 10.1152/ajprenal.00341.2012. Epub 2012 Aug 22.

3.

Differential role of melanocortin receptor subtypes in cachexia.

Marks DL, Butler AA, Turner R, Brookhart G, Cone RD.

Endocrinology. 2003 Apr;144(4):1513-23.

PMID:
12639936
4.

Role of leptin and melanocortin signaling in uremia-associated cachexia.

Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH.

J Clin Invest. 2005 Jun;115(6):1659-65.

5.

Role of the central melanocortin system in cachexia.

Marks DL, Ling N, Cone RD.

Cancer Res. 2001 Feb 15;61(4):1432-8.

6.

Effect of Agouti-related protein in regulation of the hypothalamic-pituitary-thyroid axis in the melanocortin 4 receptor knockout mouse.

Fekete C, Marks DL, Sarkar S, Emerson CH, Rand WM, Cone RD, Lechan RM.

Endocrinology. 2004 Nov;145(11):4816-21. Epub 2004 Jul 15.

PMID:
15256492
7.

Modulation of melanocortin signaling ameliorates uremic cachexia.

Cheung WW, Rosengren S, Boyle DL, Mak RH.

Kidney Int. 2008 Jul;74(2):180-6. doi: 10.1038/ki.2008.150. Epub 2008 Apr 23.

8.

The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist.

Markison S, Foster AC, Chen C, Brookhart GB, Hesse A, Hoare SR, Fleck BA, Brown BT, Marks DL.

Endocrinology. 2005 Jun;146(6):2766-73. Epub 2005 Mar 17.

PMID:
15774557
9.

Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice.

Nicholson JR, Kohler G, Schaerer F, Senn C, Weyermann P, Hofbauer KG.

J Pharmacol Exp Ther. 2006 May;317(2):771-7. Epub 2006 Jan 25.

10.

Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice.

Cheung WW, Kuo HJ, Markison S, Chen C, Foster AC, Marks DL, Mak RH.

J Am Soc Nephrol. 2007 Sep;18(9):2517-24. Epub 2007 Aug 8.

11.

Forebrain melanocortin signaling enhances the hindbrain satiety response to CCK-8.

Blevins JE, Morton GJ, Williams DL, Caldwell DW, Bastian LS, Wisse BE, Schwartz MW, Baskin DG.

Am J Physiol Regul Integr Comp Physiol. 2009 Mar;296(3):R476-84. doi: 10.1152/ajpregu.90544.2008. Epub 2008 Dec 24.

12.
13.

Update on melanocortin interventions for cachexia: progress toward clinical application.

DeBoer MD.

Nutrition. 2010 Feb;26(2):146-51. doi: 10.1016/j.nut.2009.07.003. Epub 2009 Dec 8. Review.

14.

Vitamin D signaling pathway plays an important role in the development of heart failure after myocardial infarction.

Bae S, Singh SS, Yu H, Lee JY, Cho BR, Kang PM.

J Appl Physiol (1985). 2013 Apr;114(8):979-87. doi: 10.1152/japplphysiol.01506.2012. Epub 2013 Feb 21.

15.

Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure.

Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, Hosoda H, Hirota Y, Ishida H, Mori H, Kangawa K.

Circulation. 2001 Sep 18;104(12):1430-5.

16.

Heparanase affects food intake and regulates energy balance in mice.

Karlsson-Lindahl L, Schmidt L, Haage D, Hansson C, Taube M, Egecioglu E, Tan YX, Admyre T, Jansson JO, Vlodavsky I, Li JP, Lindahl U, Dickson SL.

PLoS One. 2012;7(3):e34313. doi: 10.1371/journal.pone.0034313. Epub 2012 Mar 27. Erratum in: PLoS One. 2012;7(10). doi:10.1371/annotation/c91d94c7-fd12-4a77-ba18-d3ff4f163d72. Egeciouglu, Emil [corrected to Egecioglu, Emil].

17.

Enterostatin inhibition of dietary fat intake is modulated through the melanocortin system.

Lin L, Park M, York DA.

Peptides. 2007 Mar;28(3):643-9. Epub 2006 Nov 17.

19.

Effects of AgRP inhibition on energy balance and metabolism in rodent models.

Dutia R, Kim AJ, Modes M, Rothlein R, Shen JM, Tian YE, Ihbais J, Victory SF, Valcarce C, Wardlaw SL.

PLoS One. 2013 Jun 6;8(6):e65317. doi: 10.1371/journal.pone.0065317. Print 2013.

20.

Agouti-related protein is posttranslationally cleaved by proprotein convertase 1 to generate agouti-related protein (AGRP)83-132: interaction between AGRP83-132 and melanocortin receptors cannot be influenced by syndecan-3.

Creemers JW, Pritchard LE, Gyte A, Le Rouzic P, Meulemans S, Wardlaw SL, Zhu X, Steiner DF, Davies N, Armstrong D, Lawrence CB, Luckman SM, Schmitz CA, Davies RA, Brennand JC, White A.

Endocrinology. 2006 Apr;147(4):1621-31. Epub 2005 Dec 29.

PMID:
16384863

Supplemental Content

Support Center